You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Inluriyo ™ (imlunestrant) tablets
200 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Inluriyo™ (imlunestrant) be administered?
The recommended dosage of Inluriyo (imlunestrant) is 400 mg taken orally once daily at approximately the same time every day.
Imlunestrant Dosing and Administration
The recommended dosage of imlunestrant is 400 mg taken orally, once daily, at approximately the same time every day.1
Patients should take imlunestrant on an empty stomach at least 2 hours before food, or 1 hour after food.1
Pre/perimenopausal women and men treated with imlunestrant should receive a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.1
If a dose of imlunestrant is missed by 6 or more hours or vomiting occurs, skip the dose and take the next dose the following day at the regularly scheduled time.1
Patients should swallow the tablets whole. Do not split, crush, or chew the tablets.1
Continue treatment until disease progression or unacceptable toxicity.1
Enclosed Prescribing Information
Reference
1Inluriyo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: June 05, 2025